Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
Join Today's Clinical Lab and David Miklos, MD, PhD, to discuss recent advances in bispecific CAR-T therapy and biomarkers for characterizing CAR-T product quality
Today’s Clinical Lab is a reader-centric publication that keeps clinical professionals up to date with today’s rapidly changing lab industry with in-depth and timely editorial content and resources, including clinical industry news and insights into the latest trends, technologies, and techniques in the clinical lab.
ViewFull ProfileLearn about ourEditorial Policies.
Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy targeting the surface receptor CD19 (CAR19) is a potent treatment option for patients with relapsed or chemotherapy-refractory B cell malignancies.
Unfortunately, cancer continues to progress in a large subset of these patients due to changes in CD19 presentation on the cancer cells. To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B-cell specific cell surface molecule CD22.
While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR T-cell that simultaneously targets CD19 and CD22. In this webinar brought to you by IsoPlexis, David Miklos will discuss recent advances in bispecific CAR-T therapy development and critical functional biomarkers for characterizing CAR-T product quality.